Abiomed Third Quarter Fiscal 2013 Earnings and Conference Call Notification

Thu Jan 17, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.


DANVERS, Mass., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc
. (Nasdaq:ABMD) announced today that on Wednesday, February 6, 2013, the Company will release
financial results for the third quarter of fiscal 2013. The Company will host a conference call to
discuss the results on Wednesday, February 6, 2013, at 8:00 a.m. ET. Michael R. Minogue, Chairman,
President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial
Officer; and Susan V. Lisa, Senior Director, Investor Relations and Corporate Development, will
host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com
http://www.globenewswire.com/newsroom/ctr?d=10018380&l=2&u=http%3A%2F%2Finvestor.abiomed.com  or
dial (877) 638-9567; the international number is (253) 237-1032. A replay of this conference call
will be available beginning at 11 a.m. ET February 6, 2013 through 11:59 p.m. ET on February 13,
2013. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The
replay access code is 90622458.


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that
provide circulatory support. Our products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For additional information please visit:

The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564


This release contains forward-looking statements, including statements regarding expected patient
outcomes, development of Abiomed's existing and new products, the Company's progress toward
commercial growth, and future opportunities and expected regulatory approvals. The Company's
actual results may differ materially from those anticipated in these forward-looking statements
based upon a number of factors, including uncertainties associated with development, testing and
related regulatory approvals, including anticipated future losses, complex manufacturing, high
quality requirements, dependence on limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of additional financing, and other
risks and challenges detailed in the Company's filings with the Securities and Exchange
Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly
Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this release. The Company undertakes no obligation
to publicly release the results of any revisions to these forward-looking statements that may be
made to reflect events or circumstances that occur after the date of this release or to reflect
the occurrence of unanticipated events.

CONTACT: For further information please contact:
         Susie Lisa
         Senior Director, Investor Relations and Corporate Development
         Aimee Maillett
         Corporate Communications Manager